Cassava Sciences | PTIE - Cash And Equivalent


Cassava Sciences reported $106.08M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
Cara Therapeutics USD 21.42M 770K Sep/2025
Cassava Sciences USD 106.08M 6.3M Sep/2025
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Geron USD 79.44M 553K Dec/2025
J&J USD 21.69B 1.98B Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Novavax USD 240.63M 27.39M Dec/2025
Pfizer USD 1.7B 561M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025